Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer

Table 1

Dosimetric reduction in normal tissue radiation for proton- versus photon-based SABR plans.

Author, reference	Number of plans compared (𝑛)	Total dose, GyE (dose per fraction)	Lung reduction from protons	Esophagus reduction from protons
Hoppe et al., [25]	16	48 (12)	Mean dose 2.2 GyE; V5, 10.4%*; V10, 6.4%; V20, 2.1%
Seco et al., [26]	20	42 (14)	V5, 37.8%	Maximum dose, 68%
Georg et al., [27]	36	45 (15)	V20, PSPT, 7–9%; V20, IMPT, >10%
Register et al., [6]	45	50 (12.5)	Mean dose, 50%
Kadoya et al., [29]	21	66 (6.6)	Mean dose 2.8 GyE; V5, 18.8%; V10, 10.4%; V20, 2.3%

^∗𝑉𝑥: percentage of structure volume receiving ≥X GyE. PSPT: passively scattered proton therapy. IMPT: intensity-modulated proton therapy.